Rhumbline Advisers Has $19.34 Million Stock Position in Henry Schein, Inc. (NASDAQ:HSIC)

Rhumbline Advisers increased its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 2.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 282,315 shares of the company's stock after purchasing an additional 6,584 shares during the period. Rhumbline Advisers owned approximately 0.23% of Henry Schein worth $19,336,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of HSIC. Mather Group LLC. grew its stake in Henry Schein by 43.7% in the fourth quarter. Mather Group LLC. now owns 1,503 shares of the company's stock valued at $104,000 after acquiring an additional 457 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Henry Schein by 29.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,854 shares of the company's stock valued at $1,113,000 after purchasing an additional 3,650 shares during the last quarter. GHP Investment Advisors Inc. boosted its holdings in shares of Henry Schein by 2.2% in the 4th quarter. GHP Investment Advisors Inc. now owns 55,739 shares of the company's stock valued at $3,857,000 after buying an additional 1,176 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in Henry Schein by 3.8% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,491 shares of the company's stock valued at $934,000 after acquiring an additional 497 shares during the last quarter. Finally, Savant Capital LLC lifted its stake in Henry Schein by 43.9% in the 4th quarter. Savant Capital LLC now owns 4,651 shares of the company's stock valued at $322,000 after purchasing an additional 1,420 shares during the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Stock Down 0.1%

Shares of NASDAQ HSIC opened at $70.37 on Friday. The stock has a market capitalization of $8.57 billion, a PE ratio of 28.96, a P/E/G ratio of 2.13 and a beta of 0.87. Henry Schein, Inc. has a one year low of $60.56 and a one year high of $82.49. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. The business's fifty day moving average price is $67.77 and its 200-day moving average price is $71.63.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.04. The firm had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business's quarterly revenue was down .1% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.10 earnings per share. On average, equities research analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current year.

Wall Street Analyst Weigh In

HSIC has been the subject of a number of research reports. Piper Sandler cut their target price on shares of Henry Schein from $83.00 to $77.00 and set an "overweight" rating for the company in a research note on Wednesday, April 30th. Wall Street Zen cut shares of Henry Schein from a "buy" rating to a "hold" rating in a research report on Thursday, April 17th. UBS Group reduced their price objective on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a research report on Wednesday, February 26th. Barrington Research reduced their target price on Henry Schein from $90.00 to $86.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Finally, Wells Fargo & Company cut their price target on shares of Henry Schein from $80.00 to $75.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Six research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Henry Schein has an average rating of "Moderate Buy" and an average price target of $79.30.

Insider Transactions at Henry Schein

In other Henry Schein news, CEO Bradford C. Connett sold 4,036 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total transaction of $287,161.40. Following the transaction, the chief executive officer now owns 62,688 shares in the company, valued at approximately $4,460,251.20. This represents a 6.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Philip A. Laskawy sold 2,604 shares of the company's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the sale, the director now directly owns 24,805 shares in the company, valued at approximately $1,762,147.20. The trade was a 9.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.08% of the company's stock.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.